Role of Selected Salivary Inflammatory Cytokines in the Diagnosis and Prognosis of Oral Squamous Cell Carcinoma. A Systematic Review and Meta-analysis

Overview

Journal Med Oral Patol Oral Cir Bucal

Specialty Dentistry

Date 2023 Apr 26

PMID 37099710

Authors

E Benito-Ramal

S Egido-Moreno

B Gonzalez-Navarro

E Jane-Salas

X Rosello-Llabres

J Lopez-Lopez

Affiliations

Soon will be listed here.

Abstract

Background: Oral squamous cell carcinoma (OSCC) is gradually increasing its incidence in our society. Unfortunately, this entity is diagnosed at an advanced stage in most patients, a fact that implies greater difficulty in its treatment and a worse prognosis. This systematic review aims to assess whether the cytokines IL-6, IL-8 and TNF-α are potential salivary biomarkers that allow early diagnosis of cancer.

Material And Methods: An electronic search was performed in three databases (Pubmed, Scopus and Web of Science). We used the following keywords: "salivary cytokines", "saliva cytokines", "salivary interleukins", "biomarkers", "oral squamous cell carcinoma" and "diagnosis", combined with the Boolean operators "AND" and "OR".

Results: 128 publications were found and finally 23 articles were included in the review and 15 in the meta-analysis. It has been observed that the majority of OSCC patients express higher salivary concentrations of IL-6, IL-8 and TNF-α compared to the control (CL) and premalignant lesion (OPML) groups. It has also been observed that the different premalignant lesions do not have statistically significant differences in the salivary concentration of the cytokines, and on the other hand, differences have been observed between the different TNM stages. The meta-analysis has shown that the difference in concentration of IL-6, IL-8 and TNF-α is statistically significant between the CL group and the OSCC, and also between the CL group and OPML.

Conclusions: There is sufficient evidence to affirm that IL-6, IL-8 and TNF-α are useful salivary cytokines in the early diagnosis and prognosis of OSCC. Although future studies are necessary to establish greater reliability of these biomarkers and thus be able to develop a valid diagnostic test.

Citing Articles

Salivary miRNAs and cytokines associated with diagnosis and prognosis of oral squamous cell carcinoma.

Qin Y, Dong X, Li B Front Cell Dev Biol. 2025; 13:1531016.

PMID: 39911325 PMC: 11794800. DOI: 10.3389/fcell.2025.1531016.

Association of serum and salivary dipeptidyl peptidase-4 (DPP-4) with oral cancerous and precancerous lesions; an observational diagnostic accuracy study.

Abdel Fattah Tarrad N, Shaker O, Abdelkawy M, Hassan S BMC Oral Health. 2024; 24(1):1206.

PMID: 39390508 PMC: 11468375. DOI: 10.1186/s12903-024-04939-7.

PRF Lysates Modulate Chemokine Expression in Oral Squamous Carcinoma and Healthy Epithelial Cells.

Afradi Z, Panahipour L, Abbas Zadeh S, Gruber R Bioengineering (Basel). 2024; 11(8).

PMID: 39199704 PMC: 11351820. DOI: 10.3390/bioengineering11080746.

A Roadmap for the Rational Use of Biomarkers in Oral Disease Screening.

Cirillo N Biomolecules. 2024; 14(7).

PMID: 39062501 PMC: 11274832. DOI: 10.3390/biom14070787.

References

Dionne K, Warnakulasuriya S, Zain R, Cheong S . Potentially malignant disorders of the oral cavity: current practice and future directions in the clinic and laboratory. Int J Cancer. 2014; 136(3):503-15. DOI: 10.1002/ijc.28754. View

Brinkmann O, Kastratovic D, Dimitrijevic M, Konstantinovic V, Jelovac D, Antic J . Oral squamous cell carcinoma detection by salivary biomarkers in a Serbian population. Oral Oncol. 2010; 47(1):51-5. PMC: 3032819. DOI: 10.1016/j.oraloncology.2010.10.009. View

Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso M . Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014; 2014:149185. PMC: 4036716. DOI: 10.1155/2014/149185. View

Dineshkumar T, Ashwini B, Rameshkumar A, Rajashree P, Ramya R, Rajkumar K . Salivary and Serum Interleukin-6 Levels in Oral Premalignant Disorders and Squamous Cell Carcinoma: Diagnostic Value and Clinicopathologic Correlations. Asian Pac J Cancer Prev. 2016; 17(11):4899-4906. PMC: 5454693. DOI: 10.22034/APJCP.2016.17.11.4899. View

Rajkumar K, Nandhini G, Ramya R, Rajashree P, Ramesh Kumar A, Anandan S . Validation of the diagnostic utility of salivary interleukin 8 in the differentiation of potentially malignant oral lesions and oral squamous cell carcinoma in a region with high endemicity. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 118(3):309-19. DOI: 10.1016/j.oooo.2014.04.008. View

Singh P, Verma J, Singh J . Validation of Salivary Markers, IL-1β, IL-8 and Lgals3bp for Detection of Oral Squamous Cell Carcinoma in an Indian Population. Sci Rep. 2020; 10(1):7365. PMC: 7192911. DOI: 10.1038/s41598-020-64494-3. View

Sahebjamee M, Eslami M, AtarbashiMoghadam F, Sarafnejad A . Salivary concentration of TNFalpha, IL1 alpha, IL6, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2008; 13(5):E292-5. View

Ferrari E, Pezzi M, Cassi D, Pertinhez T, Spisni A, Meleti M . Salivary Cytokines as Biomarkers for Oral Squamous Cell Carcinoma: A Systematic Review. Int J Mol Sci. 2021; 22(13). PMC: 8267678. DOI: 10.3390/ijms22136795. View

Juretic M, Cerovic R, Belusic-Gobic M, Brekalo Prso I, Kqiku L, Spalj S . Salivary levels of TNF-α and IL-6 in patients with oral premalignant and malignant lesions. Folia Biol (Praha). 2013; 59(2):99-102. View

10.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5):336-41. DOI: 10.1016/j.ijsu.2010.02.007. View

11.

G D, Nandan S, Kulkarni P . Salivary Tumour Necrosis Factor-α as a Biomarker in Oral Leukoplakia and Oral Squamous Cell Carcinoma. Asian Pac J Cancer Prev. 2019; 20(7):2087-2093. PMC: 6745219. DOI: 10.31557/APJCP.2019.20.7.2087. View

12.

Katakura A, Kamiyama I, Takano N, Shibahara T, Muramatsu T, Ishihara K . Comparison of salivary cytokine levels in oral cancer patients and healthy subjects. Bull Tokyo Dent Coll. 2008; 48(4):199-203. DOI: 10.2209/tdcpublication.48.199. View

13.

Zanoni D, Montero P, Migliacci J, Shah J, Wong R, Ganly I . Survival outcomes after treatment of cancer of the oral cavity (1985-2015). Oral Oncol. 2019; 90:115-121. PMC: 6417804. DOI: 10.1016/j.oraloncology.2019.02.001. View

14.

Sarode G, Maniyar N, Sarode S, Jafer M, Patil S, Awan K . Epidemiologic aspects of oral cancer. Dis Mon. 2020; 66(12):100988. DOI: 10.1016/j.disamonth.2020.100988. View

15.

St John M, Li Y, Zhou X, Denny P, Ho C, Montemagno C . Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004; 130(8):929-35. DOI: 10.1001/archotol.130.8.929. View

16.

Lopez-Lopez J, Omana-Cepeda C, Jane-Salas E . [Oral precancer and cancer]. Med Clin (Barc). 2015; 145(9):404-8. DOI: 10.1016/j.medcli.2014.11.014. View

17.

Krishnan R, Thayalan D, Padmanaban R, Ramadas R, Annasamy R, Anandan N . Association of serum and salivary tumor necrosis factor-α with histological grading in oral cancer and its role in differentiating premalignant and malignant oral disease. Asian Pac J Cancer Prev. 2014; 15(17):7141-8. DOI: 10.7314/apjcp.2014.15.17.7141. View

18.

Korostoff A, Reder L, Masood R, Sinha U . The role of salivary cytokine biomarkers in tongue cancer invasion and mortality. Oral Oncol. 2011; 47(4):282-7. DOI: 10.1016/j.oraloncology.2011.02.006. View

19.

Elashoff D, Zhou H, Reiss J, Wang J, Xiao H, Henson B . Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev. 2012; 21(4):664-72. PMC: 3319329. DOI: 10.1158/1055-9965.EPI-11-1093. View

20.

Neville B, Day T . Oral cancer and precancerous lesions. CA Cancer J Clin. 2002; 52(4):195-215. DOI: 10.3322/canjclin.52.4.195. View